Do Biological Medicinal Products Pose a Risk to the Environment? Thomas C. KühlerMikael AnderssonLennart Åkerblom Current Opinion 20 November 2012 Pages: 995 - 1000
A Benefit-Risk Assessment of Imatinib in Chronic Myeloid Leukaemia and Gastrointestinal Stromal Tumours Dominik WolfHolger Rumpold Review Article 20 November 2012 Pages: 1001 - 1015
Predicting the Clinical Relevance of Drug Interactions From Pre-Approval Studies Silvio CacciaSilvio GarattiniAlessandro Nobili Review Article 20 November 2012 Pages: 1017 - 1039
Differences in Adverse Effect Reporting in Placebo Groups in SSRI and Tricyclic Antidepressant Trials Winfried RiefYvonne NestoriucJerry Avorn Original Research Article 20 November 2012 Pages: 1041 - 1056
Risk Management Policy and Black-Box Warnings Daniel M. CookRama K. GurugubelliLisa A. Bero Original Research Article 20 November 2012 Pages: 1057 - 1066
Consumer Reporting of Adverse Drug Reactions Lise AagaardLars Hougaard NielsenEbba Holme Hansen Original Research Article 20 November 2012 Pages: 1067 - 1074
Effectiveness of Safety Warnings in Atypical Antipsychotic Drugs Gabriel Sanfélix-GimenoPedro Cervera-CasinoTeresa Barbera Original Research Article 20 November 2012 Pages: 1075 - 1087
Mortality Associated with Attention-Deficit Hyperactivity Disorder (ADHD) Drug Treatment Suzanne McCarthyNoel CranswickIan C. K. Wong Original Research Article 20 November 2012 Pages: 1089 - 1096
Attention-Deficit Hyperactivity Disorder (ADHD) Treatment and Sudden Death Frank M.C. Besag Commentary 20 November 2012 Pages: 1097 - 1100